222 Third Street
Greg Weinhoff, MD
Resolvyx Pharmaceuticals, Inc.
Resolvyx Pharmaceuticals is a biopharmaceutical company dedicated to the discovery, development and commercialization of resolvins, a novel class of therapies to treat inflammatory diseases and their complications. Resolvyx's drug R&D programs are focused on characterizing and developing resolvin-based compounds. Resolvyx currently has two programs in clinical development.
Doug Cole is on the Board of Directors.